CLINICAL TRIALS PROFILE FOR BELOTECAN
✉ Email this page to a colleague
Clinical Trials for Belotecan
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00430144 ↗ | Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix | Completed | Sokbom Kang | Phase 2 | -list item one, The purpose of this study is to evaluate the overall response rate of belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix |
NCT00754858 ↗ | Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer | Completed | Yonsei University | Phase 2 | RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Belotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving belotecan together with cisplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well belotecan works when given together with cisplatin in treating patients with previously untreated extensive stage small cell lung cancer. |
NCT00826644 ↗ | Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient | Completed | Chong Kun Dang Pharmaceutical | Phase 3 | Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer. Primary endpoints - to assess Response Rate Secondary endpoints - to assess Overall response duration, Time to progression, Overall survival |
NCT00826644 ↗ | Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient | Completed | Chonnam National University Hospital | Phase 3 | Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer. Primary endpoints - to assess Response Rate Secondary endpoints - to assess Overall response duration, Time to progression, Overall survival |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Belotecan
Condition Name
Clinical Trial Locations for Belotecan
Clinical Trial Progress for Belotecan
Clinical Trial Phase
Clinical Trial Sponsors for Belotecan
Sponsor Name